Home › BioMarin's FDA Panel: Revisiting Biotech's Biggest Battle
 

Keywords :   


BioMarin's FDA Panel: Revisiting Biotech's Biggest Battle

2015-11-30 16:10:16| Biotech - Topix.net

BioMarin's exon-skipping drug, drisapersen, has occupied biotechnology investors' minds over the past week. is a debilitating muscular disease that affects boys less than 10 years of age and slowly causes progressive muscle wasting resulting in loss of walking ability, and respiratory and cardiac failure with 100% death rate within few years.

Tags: panel battle biggest fda

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
02.11Subtropical Storm Patty Graphics
02.11Atlantic Tropical Weather Outlook
02.11Eastern North Pacific Tropical Weather Outlook
02.11Tropical Storm Lane Graphics
02.11Subtropical Storm Patty Graphics
02.11Tropical Storm Lane Forecast Discussion Number 4
02.11Subtropical Storm Patty Wind Speed Probabilities Number 2
02.11Summary for Tropical Storm Lane (EP3/EP132024)
More »